Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease
(2008)
Journal Article
Wakil, A., Rigby, A. S., Clark, A. L., Kallvikbacka-Bennett, A., & Atkin, S. L. (2008). Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European journal of endocrinology, 159(4), R11-R14. https://doi.org/10.1530/eje-08-0365
OBJECTIVE: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyp... Read More about Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.